Biosimilars: Friend or foe to healthcare?
Our article in Pharma Market Europe and our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.
Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000. Biosimilars medicines, the follow-on “generics” to biologics which have come off-patent, present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems.
Annual donation made to Forever Angels baby home
Access Partnership and Research Partnership have made a seasonal donation to its chosen charity, Forever Angels this week of US$2,000.
Access Partnership and Research Partnership have made a seasonal donation to their chosen charity, Forever Angels this week of US$2,000.
Thanks to the incredible efforts of our staff, we also raised a further $1,102 for the charity through various fundraising activities, bringing our total donation this winter to $3,102. Employees have been partaking in various fundraising initiatives throughout 2013 to raise money for this worthy cause.
Pharma Payer Partnerships - Rhetoric or Reality?
“Progress is impossible without change, and those who cannot change their minds cannot change anything” George Bernard Shaw
Successful Pharma Payer Partnerships require a change in the mindset of participants from their current comfort zones - payers from a fixed focus on purely budgetary matters and pharma from providing medicines on a volume based, benefits selling basis. A consideration of the complete patient treatment journey will require fresh thinking from both stakeholders. External factors, such as a realization by Pharma that the era of the blockbuster is over, an increased patient empowerment fuelled by the Internet and the current austerity measures sweeping Western Europe, are accelerating the need for mutually beneficial partnerships.
Recently in the United Kingdom the Health and Social Care Bill 1 provided a framework to promote joint working between the NHS and the pharmaceutical industry. Its aim is to improve the innovation and delivery of healthcare through improved collaboration between the NHS and Industry.
It’s no longer “white pills for western markets”
The BioPharma industry is now in the process of re-evaluating the old business model predicated on blockbuster medicines for mature markets. In the words of GSK’s CEO Andrew Witty there is a recognised need to diversify away from the traditional “white pills & western markets” strategy, which no longer works in the new world of healthcare provision.
With the projected growth of 1st and 2nd tier Emerging Markets (EM) based upon rising GDP healthcare expenditure, many companies are now significantly investing in these developing economies. But what are the access considerations for manufacturers?
Navigating and mitigating Payer uncertainty around innovative oncology products
We have conducted many payer research projects supporting the commercialization of oncology products. During our research, payers frequently express their frustration at the apparent disconnect between a manufacturer’s pricing and market access value proposition and the clinical and economic evidence to support the manufacturer’s position.
Unfortunately our industry’s reliance on traditional qualitative payer interviews and advisory boards has left many gaps in the identification of value as defined by the payer and the “value proposition” as communicated by the manufacturer.